---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-005406"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:10:37.355711+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vanda Q4 2024 revenue $53.2M (+17% YoY); guides 2025 rev $210-250M

## Summary
- Q4 2024 net loss $4.9M vs $2.4M loss in Q4 2023; Fanapt sales $26.6M (+18% YoY).
- Full year 2024 revenue $198.8M (+3%); net loss $18.9M vs net income $2.5M in 2023.
- 2025 revenue guidance $210-250M; targets psychiatry portfolio >$750M by 2030.
- Bysanti NDA for bipolar/schizophrenia expected Q1 2025; Tradipitant NDA for motion sickness submitted Q4 2024.
- Imsidolimab BLA for generalized pustular psoriasis expected in 2025.

## SEC filing metadata
- accession: 0001628280-25-005406
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/0001628280-25-005406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/vnda-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-005406
- JSON: https://secwatch.observer/filing/0001628280-25-005406.json
- Plain text: https://secwatch.observer/filing/0001628280-25-005406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.